Future Market Insights
Search Reports

Automated Cell Therapy Processing Systems Market

Starting at US$ 5000

Buy Now
Companies
Industry Size (2025)
USD 1.79 Bn
Forecast (2035)
USD 8.5 Bn
CAGR (2025 to 2035)
16.2%

Automated Cell Therapy Processing Systems Market Size and Share Forecast Outlook 2025 to 2035

The global Automated Cell Therapy Processing Systems Market is projected to be valued at USD 1.79 billion in 2025 and is expected to reach USD 8.5 billion by 2035, registering a CAGR of 16.2% during the forecast period. This expansion is driven by the escalating demand for personalized medicine, particularly in treating chronic diseases such as cancer and autoimmune disorders.

The adoption of automated and closed systems enhances manufacturing efficiency, reduces contamination risks, and ensures compliance with Good Manufacturing Practices (GMP), thereby improving product quality and scalability. Technological advancements, including the integration of artificial intelligence and machine learning, are further streamlining cell therapy processes, leading to cost reductions and increased throughput.

Moreover, supportive regulatory frameworks and increased investments in cell and gene therapy research are fostering innovation and accelerating market growth. These factors collectively position the market for sustained expansion over the next decade.

Prominent manufacturers in this market include Thermo Fisher Scientific, Miltenyi Biotec, Lonza, Fresenius Kabi, and Cellares. These companies are actively investing in research and development to introduce advanced processing systems that enhance efficiency and scalability in cell therapy manufacturing.

Automated Cell Therapy Processing Systems Market 1
Automated Cell Therapy Processing Systems Market 1
Metric Value
Market Size (2025E) USD 1.79 Billion
Market Value (2035F) USD 8.5 billion
CAGR (2025 to 2035) 16.2%

In January 2025, CPC (Colder Products Company) launched the MicroCNX™ Nano Connector, a sterile, small-format connector designed to improve the safety and efficiency of cell and gene therapy processing. Troy Ostreng, Senior Product Manager for CPC's biopharmaceutical business, said "Now, CGT processing assemblies that include the MicroCNX Nano connectors will allow users to easily click together the connector halves to create a sterile flow path. This is a major advancement for CGT applications."

 In North America, market growth has been predominantly driven by robust investments in cell and gene therapy manufacturing capabilities. Adoption of automated and closed processing systems has been accelerated by the presence of leading biotech firms and favourable regulatory support from agencies such as the FDA, and reduced error rates. Government funding and incentives have further supported the widespread deployment of closed-system solutions across clinical trials sites and CDMO’s.

In Europe, strong adoption of Automated Cell Therapy Processing Systems has been facilitated by increasing demand for scalable CGT solutions and strict regulatory compliance under EMA guidelines. Investments have been funnelled into R&D and cleanroom automation, particularly in Germany, the UK, and the Netherlands. Funding support from regional health authorities and innovation councils has been extended to strengthen infrastructure. Rising focus on decentralized manufacturing and reduced contamination risks has reinforced the shift toward closed-loop processing technologies.

Analyzing Automated Cell Therapy Processing Systems Market by Top Investment Segments

Non-Stem Cell Therapy Leads the Market Due to Expanding Oncology Applications and Scalability Advantages

The non-stem cell therapy segment has been observed to hold the largest market share, accounting for approximately 42.1% of total revenue in 2025. This dominance has been driven by the increasing application of CAR-T and T-cell therapies in oncology, which require scalable, sterile, and automated platforms for consistent processing.

Greater clinical success rates and rapid commercialization potential have contributed to the segment’s prominence. Regulatory approvals and funding have also been directed more heavily toward non-stem cell-based products due to their therapeutic precision. Additionally, closed processing systems have been increasingly adopted to support the complex handling requirements of immune-based therapies, enhancing process efficiency and reducing contamination risks, thereby reinforcing the segment’s growth trajectory.

Pre-Commercial / R&D Scale Dominates the Market Owing to High Clinical Trial Volume and Process Optimization Needs

The pre-commercial/R&D scale segment has captured a revenue share of approximately 74.0% in 2025, primarily due to its extensive use in early-phase clinical trials and translational research. A surge in investigational cell therapy programs has led to increased deployment of closed and automated systems at small-scale facilities.

Process optimization and proof-of-concept validations have been prioritized, requiring flexible, modular systems for iterative testing. As regulatory bodies emphasize data integrity and reproducibility, automation has been adopted to ensure standardized procedures during development. Moreover, academic institutions and biotech start-ups have increasingly relied on these systems to accelerate time-to-clinic, positioning this segment as the foundation of market innovation and pipeline expansion.

Challenges and Opportunities

Challenge

High Capital Investment and Technological Complexity

Automated and closed cell therapy processing systems implementation involves considerable capital investment, which poses a hindrance to small and emerging biotech companies. Moving from manual to automated workflows requires top-of-the-line robotics, AI-assisted monitoring, and real-time control of processes, for which the upfront costs and technical complexity can be high. The challenge of ensuring adherence to evolving regulatory standards for Advanced Therapy Medicinal Products (ATMPs) also makes things more complicated. To address these challenges, companies are building modular and scalable automation solutions, enabling a gradual implementation without interfering with productive workflows already in place in factories.

Opportunity

Increasing Adoption of AI and Robotics in Cell Therapy Manufacturing

Cell therapy processing is being transformed by AI, robotics and real-time analytics, allowing for greater precision, less variability and more scalability. With the ability of AI to streamline processes, predictive analytics, automated quality controls, and real-time monitoring of critical variables, it is able to greatly enhance manufacturing efficiency. Robotic-driven closed systems increase sterility assurance, reduce contamination risk, and enable consistency across large batches. With the increased demand for automated and high-throughput cell therapy manufacturing, businesses that invest in, AI-driven automation, cloud-based bioprocessing platforms, and intelligent monitoring systems will be well-positioned for a competitive advantage in the changing market.

Country Wise Outlook

United States

The United States dominates the automated and closed cell therapy processing systems market owing to the strong biotechnology and pharmaceutical industries in the region. Growing interest in regenerative medicine and personalized therapies increases the need for cell processing automation to aid biotechnology companies in their endeavor. Moreover, the presence of several players in the industry, in addition to the high investments in cell therapy research, would further aid in the growth of the market. Similarly, favorable regulations from organizations like the FDA facilitate the transition toward closed systems in clinical and commercial applications to boost compliance and efficiency.

Country CAGR (2025 to 2035)
United States 15.4%

United Kingdom

The United Kingdom market is experiencing growth owing to the increasing government funds for cell therapy research and innovations in bioprocessing technology. An increasing number of biotech companies and research institutes are contributing to innovations in the field of automated cell processing solutions. Closed systems can be monitored in real time to ensure they meet strict regulatory requirements, ultimately leading to increased reliability and scalability of processes. Demand for platforms to manufacture cell therapy is rapidly increasing across the nation as personal medicine and immunotherapy become increasingly prevalent.

Country CAGR (2025 to 2035)
United Kingdom 21.2%

European Union

Market in European Union growing at a considerable pace, owing to rising adoption of automated and closed systems used in cell therapy manufacturing Germany, France, and Belgium are notable contributors, thanks to strong biotech ecosystems and government-backed initiatives. Growing prevalence of chronic diseases and subsequent demand for advanced regenerative medicine solutions drive demand for automated processing platforms. The European Medicines Agency (EMA) is stringent with quality control measures and this, in turn, is predicted to drive the use of closed cell therapy processing systems in the region.

Region CAGR (2025 to 2035)
European Union (EU) 22.0%

Japan

The established pharmaceutical industry in Japan and the country’s strong emphasis on regenerative medicine are expected to contribute to the growing adoption of automated and closed cell therapy processing systems. The aforementioned regulatory regime promotes innovation of biopharmaceuticals in the country with a focus on automating cell therapy manufacturing for improving precision and efficiency. Intensifying collaborations between academic research institutions and biotech firms propelling technology innovations make Japan an important market for automated cell therapy processing solutions.

Country CAGR (2025 to 2035)
Japan 12.2%

South Korea

Rapid development of biotechnology and stem cell research propelled South Korea as one of the largest markets for automated and closed cell therapy processing system. Cell and gene therapy investment is actively promoted by the government, leading to the development of new automation solutions. The country’s advanced manufacturing infrastructure and rising adoption of personalized medicine further drive up market demand. With biopharmaceutical companies ramping up production, the demand for efficient closed processing systems is on the upswing.

Country CAGR (2025 to 2035)
South Korea 22.1%

Competitive Outlook: Automated and Closed Cell Therapy Processing System Market

Cell therapy processing automated and closed cell therapy processing system is a herding step of cell therapy generation. To improve cell viability, sterility, and therapy standardization, companies are investing in automated bioprocessing, closed-system scalability, and real-time quality control solutions. Market competitiveness is fueled by novel GMP-compliant automation, AI-driven bioprocess monitoring, and single-use bioreactor innovations.

Key Segments in the Automated and Closed Cell Therapy Processing System Market

By Type:

  • Stem Cell Therapy
  • Non-Stem Cell Therapy

By Workflow:

  • Separation
  • Expansion
  • Apheresis
  • Fill-Finish
  • Cryopreservation

By Scale:

  • Pre-commercial/Research and Development Scale
  • Commercial Scale

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What was the overall size of the Automated & Closed Cell Therapy Processing System Market in 2025?

The overall market size for the Automated & Closed Cell Therapy Processing System Market was USD 1.79 Billion in 2025.

How big is the Automated & Closed Cell Therapy Processing System Market expected to be in 2035?

The Automated & Closed Cell Therapy Processing System Market is expected to reach USD 8.5 billion in 2035.

What will drive the demand for the Automated & Closed Cell Therapy Processing System Market during the forecast period?

The demand is driven by increasing adoption of cell and gene therapies, the need for contamination-free processing, rising regulatory compliance requirements, and advancements in automation to enhance efficiency and scalability.

List the top 5 countries contributing to the Automated & Closed Cell Therapy Processing System Market?

The top 5 countries driving market growth are the USA, UK, Europe, Japan, and South Korea.

Which segment is expected to lead in the Automated & Closed Cell Therapy Processing System Market?

Stem Cell Therapy segment is expected to lead in the Automated & Closed Cell Therapy Processing System Market

Preview the report firsthand - request a free sample

Get Sample

Get the brochure for pricing and purchase details.

Future Market Insights

Automated Cell Therapy Processing Systems Market